Author

J. Ortega-Montiel

3 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Sep 2026

Effects of Empagliflozin on Cardiovascular Outcomes Are Consistent Across Sociodemographic Subgroups: A Real-World Analysis From the EMPRISE Study.

OBJECTIVE We aimed to explore the heterogeneity of empagliflozin treatment effects on major adverse cardiovascular events (MACE), hospitalization for heart failure (HHF), and all-cause mortality (ACM) across sociodemographic and cardiovascular disease (CVD) subgroups of adults with type 2 diabetes (T2D). RESEARCH DES...

Sara J. Cromer, Helen Tesfaye, Hanseul Cho et al. · Diabetes Care · 0 citations

Sep 2026

Comparative Renal Effectiveness of GLP-1RA and SGLT2i in US Veterans with Type 2 Diabetes and CKD.

OBJECTIVE To address limited comparative evidence in older, clinically complex patients with type 2 diabetes and moderate-to-advanced chronic kidney disease (CKD), we compared nephroprotective outcomes after GLP-1RA versus SGLT2i initiation among US Veterans aged ≥65 years with type 2 diabetes and CKD stages 3-4 during...

P. Htoo, E. Patorno, J. Ortega-Montiel et al. · American Society of Nephrolo... · 0 citations

Open access Sep 2026

Safety of Sodium/Glucose Cotransporter 2 Inhibitors in Patients With Type 2 Diabetes and CKD.

RATIONALE & OBJECTIVE Patients with chronic kidney disease (CKD) are often underrepresented in clinical trials evaluating the safety profile of newer medication classes for type 2 diabetes (T2D). Given the high burden of comorbidities and polypharmacy in this population, further safety research is needed. This study ai...

J. Ortega-Montiel, Wajd Alkabbani, Georg Hahn et al. · American Journal of Kidney D... · 0 citations